ArticleArchives of virology2026
Molecular epidemiology and clinical characteristics of human adenovirus in children in Hangzhou (2022-2023).
Article in Archives of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Etiology and Epidemiology of Acute Lower Respiratory Infections Among Hospitalized Pediatric Patients in Northeastern China: A Retrospective Study from 2023 to 2025.Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Human adenovirus (HAdV), a leading cause of pediatric acute respiratory infections (ARIs), exhibited altered transmission patterns during the period of time in which COVID-19 nonpharmaceutical interventions (NPIs) were being applied. In this study, we investigated the molecular and clinical characteristics of pediatric HAdV infections in Hangzhou across two epidemiological phases: the 2022 group (March 2022-February 2023), representing a period of strict NPIs with initial post-policy adjustment, and the 2023 group (March 2023-February 2024), reflecting resumption of normal social activities. The retrospective analysis included 55,772 children (aged 0-16 years) with respiratory infections from the Children's Hospital of Zhejiang University School of Medicine. HAdV was detected via PCR‒capillary electrophoresis. Hexon gene sequencing and phylogenetic analysis were performed on 105 randomly selected HAdV-positive samples. In the 2022 group, the positivity rate of HAdV was 4.12% (579/14,049), whereas in the 2023 group, it was 3.59% (1,497/41,723). The peak HAdV infection rate occurred in May 2022 (6.39%, 61/955) and November 2022 (5.32%, 102/1,918). A sustained epidemic trend emerged after Oct. 2023, with a 6.08% (230/3,785) rate occurring in February 2024. HAdV-positive children were predominantly aged 3-6 years (P < 0.001), with no significant difference in the proportion of male and female patients (P > 0.05). The primary coinfections involved Mycoplasma pneumoniae. Pneumonia was the most common clinical diagnosis. Phylogenetic analysis classified 92.6% of the circulating strains as HAdV-B, with a small proportion of HAdV-C. These results offer vital evidence for optimizing the prevention and control of pediatric HAdV infections.
Indexed as
Identifiers
41566087What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.